No added value for a drug's new indication? Price should adjust, researchers say

As more follow-on treatments with incremental improvements win approval in the US and Europe, new research published yesterday notes that fewer than half of the first indication approvals for new drugs in the US and Europe were rated as having high therapeutic value.

Therapeutic value was determined in the study by ratings for first and supplemental indications made by France’s Ministry of Health and Germany’s Federal Joint Committee, based on evaluations and re-evaluations of drugs conducted and published as of December 2022.

Preview

来源: EndPoints

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP

LOG IN

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。